Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main focus: Development of novel gene-editing systems

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-MAD7

Funding stage: Private

Location: Boulder, Colorado, United States


Partners: Hunterian Medicine, Fate Therapeutics, Century Therapeutics

Inscripta is a company that aims to provide digital solutions for genome engineering using its Onyx™ platform. The CRISPR-based platform consists of an instrument, consumables, software, and assays and offers a fully automated workflow that enables massively parallel, trackable editing of single cells. The company also develops its proprietary MAD7 enzyme, which is a novel CRISPR nuclease. The company aims to enter into non-exclusive license agreements with other companies for the enzyme.



Company: Inscripta
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine